Swing Therapeutics Seed
🏦 Potential exit path: M&A
Headquarters: San Francisco, California, United States
Category: Digital Therapeutics
Funding Amount: $9M
💸 Last round was raised on August 11, 2021.
Select investors: JAZZ Venture Partners
Founded in 2019, Swing Therapeutics is developing digital treatments in disease areas where patients are not well-served. Its focus is on tackling autoimmune conditions and chronic overlapping pain conditions (COPCs) like fibromyalgia where central pain sensitization is a significant factor. The company's near-term goal is to validate its digital program for the treatment of fibromyalgia and bring it to market as an FDA-cleared, prescription-based digital therapeutic.
👥 Key people:
- Swing Therapeutics received FDA's Breakthrough Device Designation for its digital therapeutic for the management of fibromyalgia. 🔗
- The company's experienced CEO has previously held senior positions at the genomic diagnostics company Veracyte. Before that, he worked at a VC firm and McKinsey.
- The market for digital therapeutics is expected to reach $13.1 billion by 2026. 🔗
- Swing Therapeutics could be an attractive acquisition target for a major pharmaceutical company looking to expand into digital therapeutics.
Last update: September 6, 2021
Disclaimer: The content on this page is not an investment advice and does not constitute any offer or solicitation to offer or recommendation of any investment product. It is for general purposes only and does not take into account your individual needs, investment objectives and specific financial circumstances.